Larry to step down!

[Anonymous]

It's about time. This is only a PR move for Wallstreet, as he will remain on the BOD, but it is about time. Now get a CEO that is FDA friendly and let's get this 483 closed and Rytary approved.

 

[Anonymous]

The danger of a new CEO is that he/she may see the millions of dollars pouring down the brand drain and do what Larry should have done last year and that is to sell Rytary, in its entirety, close the failing brand division and stay with the business that has made the company all of its money - generics. Dave Doll was right.

 

[Anonymous]

Doubtful as they cannot resume growing new generic business without correcting the same issues that are holding up Rytary. Rytary will put $400 million in sales to the company so why on earth would a new CEO do that? Also, any new CEO is going to know coming in that the company is looking to become a Branded Company so I do not think they will have a choice.

 

[Anonymous]

By implication, both Rytary and the generic business are in the same predicament. If the manfr. issues are not resolved, the whole company comes to a grinding halt. No resolution = no more generic growth = no Rytary = no $400M revenue (gross overestimation for a me-too CD/LD drug, as many neuros have stated. Probably closer to $250M, at best). Larry's retirement announcement is just a small way to appease the street. Available cash went from $450 million to $250 million within a couple of months. As every month passes with no resolution to the 483 letter, the cash has to be spent. Very scary. The next quarterly figures will be very interesting.